Cargando…

First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors

EP4, a prostaglandin E(2) receptor, has shown an immunosuppressive activity on cancer cells. This first‐in‐human study evaluated ONO‐4578, a highly selective EP4 antagonist, as monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors. A daily dose ranging fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iwasa, Satoru, Koyama, Takafumi, Nishino, Makoto, Kondo, Shunsuke, Sudo, Kazuki, Yonemori, Kan, Yoshida, Tatsuya, Tamura, Kenji, Shimizu, Toshio, Fujiwara, Yutaka, Kitano, Shigehisa, Shimomura, Akihiko, Sato, Jun, Yokoyama, Fumiharu, Iida, Hiroyuki, Kondo, Maki, Yamamoto, Noboru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807514/ https://www.ncbi.nlm.nih.gov/pubmed/36082616 http://dx.doi.org/10.1111/cas.15574

Ejemplares similares

First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors
por: Kondo, Shunsuke, et al.
Publicado: (2021)

First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors
por: Koyama, Takafumi, et al.
Publicado: (2020)

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
por: Ebata, Takahiro, et al.
Publicado: (2019)

The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
por: Yonemori, Kan, et al.
Publicado: (2021)

A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2021)

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan
por: Shimomura, Akihiko, et al.
Publicado: (2017)

Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
por: Sato, Jun, et al.
Publicado: (2022)

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies
por: Kitano, Shigehisa, et al.
Publicado: (2020)

Practical consideration for successful sequential tumor biopsies in first-in-human trials
por: Koyama, Takafumi, et al.
Publicado: (2022)

Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials
por: Fujiwara, Yutaka, et al.
Publicado: (2020)

Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
por: Ida, Hanae, et al.
Publicado: (2023)

4578 Early life stress promotes chronicity of experimental colitis
por: Muir, Rachel Quinn, et al.
Publicado: (2020)

Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials
por: Takamizawa, Shigemasa, et al.
Publicado: (2022)

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
por: Callahan, Margaret K, et al.
Publicado: (2013)

Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07)
por: Satoh, Taroh, et al.
Publicado: (2021)

Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital
por: Uehara, Yuji, et al.
Publicado: (2023)

Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies
por: Horinouchi, Hidehito, et al.
Publicado: (2019)

Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies
por: Saka, Hideo, et al.
Publicado: (2020)

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
por: Kimbara, Shiro, et al.
Publicado: (2018)

Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
por: Seo, Takuji, et al.
Publicado: (2020)

Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
por: Kondo, Shunsuke, et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
por: Kuboki, Yasutoshi, et al.
Publicado: (2022)

Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
por: Nakamura, Yoshio, et al.
Publicado: (2016)

Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study
por: Shimizu, Toshio, et al.
Publicado: (2022)

Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)
por: Katakami, Nobuyuki, et al.
Publicado: (2017)

Effects of the Cathepsin K Inhibitor ONO-5334 and Concomitant Use of ONO-5334 with Methotrexate on Collagen-Induced Arthritis in Cynomolgus Monkeys
por: Yamada, Hiroyuki, et al.
Publicado: (2019)

Innovative therapeutic strategy using prostaglandin I(2) agonist (ONO1301) combined with nano drug delivery system for pulmonary arterial hypertension
por: Kanaya, Tomomitsu, et al.
Publicado: (2021)

A novel prostaglandin I(2) agonist, ONO-1301, attenuates liver inflammation and suppresses fibrosis in non-alcoholic steatohepatitis model mice
por: Motegi, Satoko, et al.
Publicado: (2022)

Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study
por: Kawai, Akira, et al.
Publicado: (2021)

Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2018)

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
por: Postow, Michael A, et al.
Publicado: (2014)

Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment
por: Watanuki, Rurina, et al.
Publicado: (2020)

HIV incidence and sexual behavioral correlates among 4578 men who have sex with men (MSM) in Chengdu, China: a retrospective cohort study
por: You, Xinyi, et al.
Publicado: (2021)

Clinical Development of Immune Checkpoint Inhibitors
por: Ito, Ayumu, et al.
Publicado: (2015)

Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer
por: Ozaki, Yukinori, et al.
Publicado: (2022)

Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials
por: Koyama, Takafumi, et al.
Publicado: (2019)

First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the ONO‐4538‐52/TASUKI‐52 randomized controlled trial
por: Kim, Hye Ryun, et al.
Publicado: (2023)

Synthesis and Applications of (ONO Pincer)Ruthenium‐Complex‐Bound Norvalines
por: Isozaki, Katsuhiro, et al.
Publicado: (2016)

Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site
por: Kodaira, Makoto, et al.
Publicado: (2018)

Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study)
por: Yamazaki, Naoya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2imhgivitim44qna2hq4046340